Health Care Cost
Sanofi announces insulin price cuts, $35 monthly cap for people with commercial insurance
Following on the heels of Eli Lilly and Novo Nordisk, Sanofi announced it will reduce the price of two of its branded insulins as well as cap out-of-pocket costs at $35 per month for people with commercial health insurance.
Patients with CKD, metabolic acidosis have increased adverse kidney outcomes, costs
Among patients with chronic kidney disease, the presence of metabolic acidosis is associated with an increased risk of adverse kidney outcomes and health care costs, according to data published in Kidney Medicine.
Novo Nordisk to cut prices by up to 75% for some insulin products in 2024
Novo Nordisk is the latest company to announce a large reduction in insulin prices as it stated it will cut prices for multiple insulin products by up to 75% in 2024.
Inflation Reduction Act may save drug costs for older patients at high CV risk
NEW ORLEANS — Medicare beneficiaries at high CV risk spending more than $2,000 per year in out-of-pocket drug costs could save a median of $855 per year under the Inflation Reduction Act, researchers reported.
Eliminating copays for common heart, diabetes drugs does not improve CV outcomes
NEW ORLEANS — Eliminating monthly copays for 15 classes of common heart and diabetes medications did not improve clinical outcomes or reduce health care costs, despite a modest improvement in medication adherence, researchers reported.
Eli Lilly announces $35 out-of-pocket insulin cap for people with commercial insurance
Adults with diabetes with commercial health insurance who use insulin manufactured by Eli Lilly and Company will have out-of-pocket costs capped at $35 per month, according to a company press release.
Point-of-care troponin may be safe, cost-saving method to rule out NSTEACS
Point-of-care troponin measurement by ambulance paramedics to rule out non-ST-elevation ACS in low-risk patients may reduce health care costs with similar 30-day adverse event risk vs. a direct-to-ED strategy, researchers reported.
Dedicated AF center reduces hospital costs, readmissions
Directing patients with atrial fibrillation who presented to the ED to follow‐up at a dedicated AF center reduced overall costs, subsequent inpatient admissions and total length of hospital stay compared with usual care, data show.
Amgen’s acquisition of Horizon could have ‘downstream effects’ in rheumatology
The recent acquisition of Horizon Therapeutics by Amgen continues a trend in medical finance that may have implications for both rheumatologists and their patients.
HHS proposes rule to strengthen contraceptive access
HHS proposed a rule Monday that aims to bolster access to birth control coverage under the Affordable Care Act, an issue of “heightened importance,” according to the agency.